Repurposing and Rescuing of Mibefradil, an Antihypertensive, for Cancer: A Case Study
- 1 December 2015
- journal article
- case report
- Published by SAGE Publications in ASSAY and Drug Development Technologies
- Vol. 13 (10) , 650-653
Abstract
The expanding “valley of death” in drug development is leaving potentially life-saving new chemical entities and molecular targets fallow. This situation is forcing early-stage companies to think creatively about moving their technologies forward, especially as institutional investors show more interest in later stages of development. Drug repurposing, a strategy to examine existing drugs for therapeutic value against different diseases, is an emerging method to bring an off-market drug back onto the market. Tau Therapeutics LLC identified the role of T-type calcium channel blockers (Cav3) in cancer proliferation, but the company was unable to attract funding while having both a nonvalidated drug target and new chemical entities. To change the risk profile of the company, Tau set out to repurpose the known Cav3 drug mibefradil as a proof of concept for the treatment of cancer. Mibefradil was launched for hypertension in the 1990s but withdrawn because of drug–drug interactions. A new sequential combination treatment, termed Interlaced Therapy™, uses short-term administration of mibefradil to enhance the overall therapeutic potential of conventional anticancer agents. Mibefradil is currently in a phase Ib clinical trial with the National Cancer Institute (NCI) Adult Brain Tumor Consortium. Mibefradil has been repurposed from an abandoned antihypertensive to a targeted solid tumor treatment, and it has been rescued from drug–drug interactions by using short-term dose exposure. Tau is using the early success of mibefradil as a proof of concept to build a platform technology of Cav3 blockers for broad antitumor applications in combination with new targeted cancer therapies, well-established chemotherapies, and radiation.Keywords
This publication has 8 references indexed in Scilit:
- Sequential therapy with the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas: An Adult Brain Tumor Consortium phase I study (ABTC1101).Journal of Clinical Oncology, 2013
- A model for the regulation of T-type Ca2+channels in proliferation: roles in stem cells and cancerExpert Review of Anticancer Therapy, 2013
- Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine modelJournal of Neuro-Oncology, 2012
- Abstract LB-262: Targeting T-type calcium channels induces the extrinsic apoptotic pathway and sensitizes glioblastoma cancer cells to radio- and chemotherapyCancer Research, 2012
- Diagnosing the decline in pharmaceutical R&D efficiencyNature Reviews Drug Discovery, 2012
- The role of voltage gated T-type Ca2+ channel isoforms in mediating “capacitative” Ca2+ entry in cancer cellsCell Calcium, 2004
- Molecular Pharmacology of T-type Ca2+ ChannelsThe Japanese Journal of Pharmacology, 2001
- Mibefradil Block of Cloned T-Type Calcium ChannelsThe Journal of Pharmacology and Experimental Therapeutics, 2000